David Young Processa Pharmaceuticals, Inc. (PCSA) insider trading activity

David Young is Pres. Research & Development of Processa Pharmaceuticals, Inc.. Currently has a direct ownership of 217,332 shares of PCSA, which is worth approximately $45,639. The most recent transaction as insider was on Apr 01, 2025, when has been sold 5,345 shares (Common Stock) at a price of $0.41 per share, resulting in proceeds of $2,191. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 217K

0% 3M change

168.63% 12M change

Total Value Held $45,639

David Young Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 01 2025	SELL Payment of exercise price or tax liability	$2,191 $0.41 p/Share	5,345 Reduced 2.4%	217,332 Common Stock
Apr 01 2025	BUY Exercise of conversion of derivative security	-	17,272 Added 7.2%	222,677 Common Stock
Jan 27 2025	BUY Open market or private purchase	$99,600 $0.8 p/Share	124,500 Added 37.74%	205,405 Common Stock
Jul 10 2024	SELL Payment of exercise price or tax liability	$482 $1.71 p/Share	282 Reduced 0.35%	80,905 Common Stock
Jul 10 2024	BUY Exercise of conversion of derivative security	-	644 Added 0.79%	81,187 Common Stock
Apr 05 2024	SELL Payment of exercise price or tax liability	$1,445 $2.79 p/Share	518 Reduced 0.64%	80,543 Common Stock
Apr 05 2024	BUY Exercise of conversion of derivative security	-	1,675 Added 2.02%	81,061 Common Stock
Feb 07 2024	BUY Open market or private purchase	$51,450 $2.45 p/Share	21,000 Added 20.92%	79,387 Common Stock
Feb 06 2024	BUY Open market or private purchase	$50,599 $2.53 p/Share	20,000 Added 25.51%	58,387 Common Stock
Jan 01 2024	SELL Payment of exercise price or tax liability	$1,445 $2.79 p/Share	518 Reduced 0.64%	80,544 Common Stock
Jan 01 2024	BUY Exercise of conversion of derivative security	-	1,675 Added 2.02%	81,062 Common Stock
Oct 12 2023	BUY Grant, award, or other acquisition	$45,030 $0.29 p/Share	155,277 Added 16.82%	767,701 Common Stock
Oct 10 2023	BUY Grant, award, or other acquisition	$34,080 $0.24 p/Share	142,000 Added 18.82%	612,424 Common Stock
Jun 12 2023	BUY Open market or private purchase	$32,000 $0.8 p/Share	40,000 Added 7.84%	470,424 Common Stock
Apr 14 2023	BUY Open market or private purchase	$11,000 $0.55 p/Share	20,000 Added 4.44%	430,424 Common Stock
Apr 13 2023	BUY Open market or private purchase	$9,600 $0.48 p/Share	20,000 Added 4.65%	410,424 Common Stock
Apr 12 2023	BUY Open market or private purchase	$9,000 $0.45 p/Share	20,000 Added 4.87%	390,424 Common Stock
Apr 11 2023	BUY Open market or private purchase	$10,400 $0.52 p/Share	20,000 Added 5.12%	370,424 Common Stock
Feb 09 2023	BUY Grant, award, or other acquisition	$15,000 $0.8 p/Share	18,750 Added 5.08%	350,424 Common Stock
Aug 16 2022	SELL Bona fide gift	-	9,250 Reduced 2.39%	377,784 Common Stock
Aug 05 2022	SELL Payment of exercise price or tax liability	$8,023 $3.17 p/Share	2,531 Reduced 0.65%	387,034 Common Stock
Aug 05 2022	BUY Exercise of conversion of derivative security	-	7,601 Added 1.91%	389,565 Common Stock
Aug 05 2021	BUY Grant, award, or other acquisition	-	7,601 Added 1.95%	381,964 Common Stock
Jun 23 2021	BUY Open market or private purchase	$76,700 $7.67 p/Share	10,000 Added 2.82%	345,190 Common Stock

David Young

Pres. Research & Development

Hanover, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PCSA shares.

Notify only if

Value

Insider Trading

Get notified when an Processa Pharmaceuticals, Inc. insider buys or sells PCSA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Processa Pharmaceuticals, Inc.

Track Activities on PCSA

Account